skip to Main Content

South San Francisco, CA, December 23, 2019 – FlemingMartin is pleased to announce that Global Blood Therapeutics (NASDAQ: GBT), a biopharmaceutical company committed to helping underserved patient communities by revolutionizing the treatment of severe blood-based conditions, has hired Kirstin Arnold to be their new Senior Director of Total Rewards.

“GBT” is poised for continued growth and success as the Company commercializes Voxelotor (Oxbryta), which was granted accelerated approval by the FDA in late November for the treatment of sickle cell disease. Kirstin will hold responsibility for the Company’s total rewards function, leading all strategy, planning, design, and development.

Kirstin possesses nearly two decades of total rewards leadership experience from multiple industries, working both in-house and as a consultant. Most recently, she built the total rewards function from the ground up at Salesforce.org. In prior positions, she developed a broad range of global compensation, benefits, equity, and recognition programs with Juniper Networks, Williams-Sonoma, and Salesforce.com, as well as with Mercer Consulting. Kirstin is a graduate of the University of British Columbia.

 

GBT logoGlobal Blood Therapeutics (GBT) is a mission-driven biopharmaceutical company committed to helping underserved patient communities by revolutionizing the treatment of severe blood-based conditions. The Company’s lead product, Voxelotor, was recently approved by the FDA as a first-of-its-kind therapy for Sickle Cell Disease.

 

Fleming Martin Color Logo Medium 72 ppiFlemingMartin is a leading retained executive search firm with offices in Northern and Southern California. FlemingMartin partners with Boards, Private Equity Firms and CEOs of companies to build successful execution-focused management teams. FlemingMartin focuses in the Technology, Manufacturing, and Consumer Products & Services industries. The Firm’s principals are trusted advisors and business partners who enable companies to gain powerful, far-reaching, and lasting contributions from their executive-level human capital.

Back To Top